MALVERN, PA, May 29, 2013 — PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes, will present at the Jefferies 2013 Global Healthcare Conference in New York on Wednesday, June 5, 2013 at 12:30 p.m. ET. Jonathan P. Mow, chief business officer, PhaseBio, will present a Company overview. A copy of the presentation will be available on the Company’s website at www.phasebio.com shortly afterwards.
PhaseBio is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes, metabolic and cardiovascular disease. The Company’s proprietary platform technology uses elastin-like biopolymers (ELPs) to control the half-life, bioavailability and physical characteristics of the molecule for ease of administration. The resulting drug products are tuned for a specific rate of absorption, thereby potentially increasing efficacy and reducing side effects. The Company’s lead development candidates are PB1023, a once-weekly GLP-1 analogue for type 2 diabetes; PE0139, a novel basal insulin ELP-fusion; and Vasomera, a weekly vasoactive intestinal peptide (VIP) agonist for acute and chronic heart failure and pulmonary arterial hypertension. PhaseBio is privately owned with headquarters and research laboratories in Malvern, Pennsylvania.